Clinical Implications of CD30 Expression in Aggressive B-cell Lymphomas

FDA approval of Brentuximab for treatment of CD30+ relapsed/refractory lymphomas initiated research focused on CD30 expression in lymphomas. Several studies examined CD30 expression in subsets of DLBCL. In our study we have expanded this research by studying CD30 expression in other types of aggressive B-cell lymphomas, including Burkitt lymphomas, high grade Follicular Lymphomas, FL3/DLBCL, DLBCL type PTLDs and PMBLs.

Source: Clinical Lymphoma, Myeloma and Leukemia - May 8, 2016 Category: Hematology Authors: Jozef Malysz, Patrick Erdman, Jeremy Klapper, Junjia Zhu, Michael Creer, Michael G. Bayerl Tags: Original Study Source Type: research